Abstracts tagged "scleroderma and treatment options"

Abstract Number: 2671 • ACR/ARHP Annual Meeting 2017
Bosentan in Scleroderma Renal Crisis: A National Open Label Prospective Study
Alice Bérezné^1,2, Hendy ABDOUL³, Alexandre Karras⁴, Isabelle Marie⁵, Antoine Huart⁶, Maxence Ficheux⁷, Viviane Queyrel⁸, Bernard Imbert⁹, Xavier Puéchal¹, Arnaud Hot¹⁰, Boris Bienvenu¹¹, Elisabeth Diot¹², Bruno Moulin¹³, Thomas Quémeneur¹⁴, Jean-Emmanuel Kahn¹⁵, Luc Mouthon¹ and Loïc Guillevin for the French Vasculitis Study Group¹, ¹Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ²Centre de Compétence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Centre de Compétence Eosinophiles CEREO, Hôpital Annecy Genevois, Anency, France, ³Centre d'investigation Clinique Paris Descartes, Necker–Cochin, Paris, Unité de Recherche Clinique, paris, France, ⁴Nephrology, HEGP, Paris, France, ⁵Internal medicine, Hôpital Bois Guillaume, ROUEN, France, ⁶Nephrology, Hôpital Rangueil, Toulouse, France, ⁷Nephrologie, Hôpital Clémenceau, CAEN, France, ⁸Internal medicine, Hôpital de l'Archet, NICE, France, ⁹Grenoble, Grenoble, France, ¹⁰Department of Internal Medicine, Edouard Herriot University Hospital, Hospices Civils de Lyon, Lyon cedex 03, France, ¹¹Internal Medicine, Hôpital de la côte de Nacre, Caen, France, ¹²Pôle médecine interne et gériatrique, pneumologie, Hôpital Bretonneau, Tours, France, ¹³Nephrology, Hôpital Civil, STRASBOURG, France, ¹⁴Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, ¹⁵foch hospital, foch, France
Background/Purpose: Scleroderma renal crisis (SRC), a life-threatening complication of systemic sclerosis (SSc), arises despite therapy combining an angiotensin-converting–enzyme inhibitor (AECI) and/or dialysis. Endothelin-1 (ET-1), a…
Abstract Number: 2179 • ACR/ARHP Annual Meeting 2013
Consensus: What Agent To Use When First-Line Vasodilatadors Fail In Raynaud´s Phenomenon Or Digital Ulcers Secondary To Juvenile Systemic Sclerosis?
Marìa M. Katsicas¹, Mariana Gonzalez² and Ricardo A. G. Russo³, ¹Immunology & Rheumatology., Hospital de Pediatrìa Garrahan, Buenos Aires, Argentina, ²Immunology & Rheumatology, Hospital de Pediatría Garrahan, Buenos Aires, Argentina, ³Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina
Background/Purpose: Juvenile Systemic Sclerosis (JSS) is characterized by Raynaud`s phenomenon (RP) and digital ulcers (DU).Conventional therapy includes calcium channel blockers (CCB). A growing number of…